跳至主要内容
临床试验/NCT06589505
NCT06589505招募中2 期

A Multicenter, Randomized, Double-blind, Parallel-group Comparative Study to Assess Efficacy and Safety of Software as a Medical Device in Patients With Post-Traumatic Stress Disorder (PTSD)

Otsuka Medical Devices Co., Ltd. Japan66 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2024年9月1日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
52
试验地点
66
主要终点
Clinician-Administered PTSD Scale for DSM-5

研究概览

简要总结

To evaluate the efficacy and safety of Software as a Medical Device in patients with Post-Traumatic Stress Disorder (PTSD)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of PTSD according to the DSM-5
  • Subjects who are within 1 to 20 years since index trauma

排除标准

  • Subjects diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, bipolar I disorder, autism spectrum disorder, or intellectual disability based on DSM-
  • Subjects diagnosed with any mood disorder and anxiety disorder according to DSM-5 that is the primary focus of treatment in the last 6 months prior to screening, as per the clinical judgement of the investigator
  • Subjects who have completed two or more full courses of trauma-focused therapy in the past

结局指标

主要结局

Clinician-Administered PTSD Scale for DSM-5

时间窗: baseline and after intervention (up to 21 weeks)

The primary objective of this study is to assess the change from baseline of the Clinician Administered PTSD Scale (CAPS - 5) score. Scores range from 0 - 80, with higher scores indicating increased PTSD symptom severity.

次要结局

未报告次要终点

研究者

发起方
Otsuka Medical Devices Co., Ltd. Japan
申办方类型
Industry
责任方
Sponsor

研究点 (66)

Loading locations...

相似试验